Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...